Glycotope GmbH, a global leader in optimizing the sugar chains (glycosylation) of biopharmaceuticals, announced full details of first-in-man Phase I trial data for CetuGEXTM, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) with optimized and fully human glycosylation...